NeoGenomics, Inc.
NASDAQ:NEOMedical - Diagnostics & Research
+$0.63 today
- Market cap
- $1.99B
- Beta
- 1.81
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.84
Volume 1.09M
Average 1.94M
NEO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
NeoGenomics, Inc.NASDAQ: NEO
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $8.22M (cash outflow) rose 30.0% year over year, ahead of the -11.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 64.4% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Capital expenditures amounted to 3.7% of revenue in FY2025, down 2.5 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +30.0% holds above the trailing-twelve-month pace of -11.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (27.01M) USD
- Year-over-year change
- +34.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.01M) | +34.2% |
| FY2024 | 2024-12-31 | (41.06M) | -42.8% |
| FY2023 | 2023-12-31 | (28.75M) | +6.9% |
| FY2022 | 2022-12-31 | (30.89M) | +51.8% |
| FY2021 | 2021-12-31 | (64.14M) | — |
Capital Expenditures vs competitors
How NEO compares with its peers on the latest reported figures
- NEO's LTM Jun 2026 capital expenditures of $29.4M is the 3rd largest of the 10 companies compared; the peer median is $12.93M.
- Its year-over-year change of -11.5% is the 7th highest of 10, against a peer median of +36.2%.
- Capital expenditures amounts to 3.8% of revenue for NEO, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $58.67M | +49.2% | -14.6% | 4.6% | |
| LTM Mar 2026 | $43.74M | +82.9% | +85.6% | 12.9% | |
| LTM Jun 2026 | $29.4M | -11.5% | -4.4% | 3.8% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $27.09M | +122.1% | +9.9% | 6.0% |
| LTM Mar 2026 | $23.2M | -21.1% | -29.9% | 2.8% | |
| LTM Jun 2026 | $12.93M | +36.2% | +4.2% | 2.3% | |
| LTM Mar 2026 | $5.19M | +29.3% | -55.1% | 8.0% | |
| LTM Mar 2026 | $756K | +39.5% | -47.1% | 1.1% | |
| LTM Jun 2026 | $504K | -70.4% | -65.9% | 0.3% | |
| LTM Mar 2026 | $411K | -87.6% | -51.5% | 0.4% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding NEO) | $12.93M | +36.2% | -29.9% | 2.8% | |
Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.35M) | (144.25M) | (87.97M) | (78.73M) | (108.03M) |
| Depreciation & Amortization | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M |
| Deferred Income Tax | 0 | (16.1M) | 0 | 0 | 0 |
| Stock-Based Compensation | 22.46M | 24.67M | 24.63M | 33.41M | 41.32M |
| Change in Working Capital | (4.6M) | (31.7M) | (25.49M) | (32.63M) | (32.1M) |
| Accounts Receivables | (4.69M) | (7.58M) | (11.52M) | (19.31M) | (6.18M) |
| Inventory | 1.63M | (1.1M) | (454K) | (2.7M) | (1.54M) |
| Accounts Payables | 19.33M | 2.8M | (4.55M) | (4M) | (4.69M) |
| Other Working Capital | (20.87M) | (25.82M) | (8.98M) | (6.62M) | (19.68M) |
| Other Non-Cash Items | (89.59M) | 31.95M | 14.29M | 12.42M | 36.21M |
| Operating Cash Flow | (26.72M) | (65.99M) | (1.95M) | 7.02M | 5.23M |
| Capital Expenditures | (64.14M) | (30.89M) | (28.75M) | (41.06M) | (27.01M) |
| Acquisitions (Net) | (419.4M) | 0 | 0 | 0 | (6.45M) |
| Purchases of Investments | (196.79M) | (97.61M) | (6.76M) | 0 | (500K) |
| Sales of Investments | 62.97M | 116.92M | 112.22M | 53.92M | 20.06M |
| Other Investing Activities | (15M) | 12.1M | 0 | 0 | 1.57M |
| Investing Cash Flow | (632.37M) | 517K | 76.71M | 12.86M | (12.34M) |
| Debt Repayment | 334.41M | (758K) | (70K) | 0 | (201.25M) |
| Common Stock Issued | 423.21M | 12.59M | 4.62M | 4.65M | 962K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (32.34M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 725.29M | 11.83M | 4.55M | 4.65M | (200.29M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 66.2M | (53.65M) | 79.31M | 24.52M | (207.39M) |
| Free Cash Flow | (90.87M) | (96.88M) | (30.71M) | (34.04M) | (21.78M) |
NeoGenomics, Inc.
NASDAQ:NEO
Intrinsic Alpha fair value
Locked
Current Price
$15.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.